To explore potential therapeutic interventions, we evaluated CPI-0610, a BET inhibitor targeting BRD4, as a novel treatment strategy for arsenical-induced pulmonary fibrosis (PF). The gene discussed is BRD4; the disease is pulmonary fibrosis.